Akorn reports record consolidated income of $73.9 million in first quarter 2013 Akorn, Inc. , a niche generic pharmaceutical company, today reported financial results because of its first quarter ended March 31, 2013. Raj Rai, Chief Executive Officer, commented, ‘We are pleased with our first one fourth results although we had been behind in the launches of particular products which were approved late this past year due to capacity constraints with our contract manufacturing partners along with market challenges. We expect resolution in the second half of this year sometime. We are also excited about the establishment of our brand-new R&D center in Vernon Hills, Illinois.Limor Shiposh, ASI’s CEO said, ‘We are very happy to have received an additional and essential FDA clearance. We intend to increase our portfolio of FDA cleared equipment inside our GenASIs platform to raised serve our customers in achieving even more accurate clinical outcomes, quicker and more price effectively. I am confident that this addition can help further create ASI as the globe leaders in automated and manual FISH imaging and analysis.’.
ASTRO: Sexual function does not decline in prostate cancers patients receiving EBRT Sexual function in prostate cancer patients receiving exterior beam radiation therapy decreases within the first 2 yrs after treatment but then stabilizes and will not continuously decline as was previously thought, according to a report in the January 1 problem of the International Journal of Radiation Oncology*Biology*Physics, the state journal of the American Society for Radiation Oncology .